• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病和弥漫性路易体病大脑中路易小体中的14-3-3蛋白。

14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains.

作者信息

Kawamoto Yasuhiro, Akiguchi Ichiro, Nakamura Shinichi, Honjyo Yasuyuki, Shibasaki Hiroshi, Budka Herbert

机构信息

Department of Neurology, Faculty of Medicine, Kyoto University, Japan.

出版信息

J Neuropathol Exp Neurol. 2002 Mar;61(3):245-53. doi: 10.1093/jnen/61.3.245.

DOI:10.1093/jnen/61.3.245
PMID:11895039
Abstract

Several components of Lewy bodies have been identified, but the precise mechanism responsible for the formation of Lewy bodies remains undetermined. The 14-3-3 protein family is involved in numerous signal transduction pathways and interacts with alpha-synuclein, which is a major constituent of Lewy bodies. To elucidate the role of 14-3-3 proteins in neuro-degenerative disorders associated with Lewy bodies, we performed immunohistochemical studies on 14-3-3 in brains from 5 elderly control subjects and from 10 patients with Parkinson disease (PD) or diffuse Lewy body disease (DLBD). In the normal controls, 14-3-3-like immunoreactivity was mainly observed in the neuronal somata and processes in various cortical and subcortical regions. In the PD and DLBD cases, a similar immunostaining pattern was found and immunoreactivity was generally spared in the surviving neurons from the severely affected regions. In addition, both classical and cortical Lewy bodies were intensely immunolabeled and some dystrophic neurites were also immunoreactive for 14-3-3. Our results suggest that 14-3-3 proteins may be associated with Lewy body formation and may play an important role in the pathogenesis of PD and DLBD.

摘要

路易小体的几种成分已被确定,但路易小体形成的确切机制仍未明确。14-3-3蛋白家族参与众多信号转导途径,并与α-突触核蛋白相互作用,而α-突触核蛋白是路易小体的主要成分。为阐明14-3-3蛋白在与路易小体相关的神经退行性疾病中的作用,我们对5名老年对照受试者以及10名帕金森病(PD)或弥漫性路易体病(DLBD)患者的大脑进行了14-3-3免疫组化研究。在正常对照中,14-3-3样免疫反应主要见于各皮质和皮质下区域的神经元胞体和突起。在PD和DLBD病例中,发现了类似的免疫染色模式,且在严重受累区域存活的神经元中免疫反应性通常得以保留。此外,经典型和皮质型路易小体均被强烈免疫标记,一些营养不良性神经突对14-3-3也有免疫反应。我们的结果表明,14-3-3蛋白可能与路易小体形成有关,并可能在PD和DLBD的发病机制中起重要作用。

相似文献

1
14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains.帕金森病和弥漫性路易体病大脑中路易小体中的14-3-3蛋白。
J Neuropathol Exp Neurol. 2002 Mar;61(3):245-53. doi: 10.1093/jnen/61.3.245.
2
Colocalization of tau and alpha-synuclein epitopes in Lewy bodies.路易小体中tau蛋白和α-突触核蛋白表位的共定位。
J Neuropathol Exp Neurol. 2003 Apr;62(4):389-97. doi: 10.1093/jnen/62.4.389.
3
Glial involvement in diffuse Lewy body disease.胶质细胞在弥漫性路易体病中的作用。
Acta Neuropathol. 2003 Feb;105(2):163-9. doi: 10.1007/s00401-002-0622-9. Epub 2002 Oct 25.
4
Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.帕金森病和皮质路易体病中的黑质和皮质路易小体以及营养不良性黑质神经突含有α-突触核蛋白免疫反应性。
J Neuropathol Exp Neurol. 1998 Apr;57(4):334-7. doi: 10.1097/00005072-199804000-00005.
5
Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.散发性帕金森病和路易体痴呆患者路易小体中磷酸化tau蛋白和NACP/α-突触核蛋白表位的细胞共定位。
Brain Res. 1999 Oct 2;843(1-2):53-61. doi: 10.1016/s0006-8993(99)01848-x.
6
Accumulation of NACP/alpha-synuclein in lewy body disease and multiple system atrophy.路易体病和多系统萎缩中NACP/α-突触核蛋白的积聚。
J Neurol Neurosurg Psychiatry. 2000 May;68(5):605-8. doi: 10.1136/jnnp.68.5.605.
7
Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies.聚集素/载脂蛋白J与皮质路易小体相关:α-突触核蛋白病病例的免疫组织化学研究
Acta Neuropathol. 2002 Sep;104(3):225-30. doi: 10.1007/s00401-002-0546-4. Epub 2002 May 9.
8
Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.在路易体病中,β淀粉样蛋白沉积与皮质α-突触核蛋白损伤增强有关。
Neurobiol Aging. 2005 Aug-Sep;26(8):1183-92. doi: 10.1016/j.neurobiolaging.2004.10.006. Epub 2004 Dec 28.
9
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.散发性帕金森病和路易体痴呆患者路易小体中α-突触核蛋白的聚集。
Am J Pathol. 1998 Apr;152(4):879-84.
10
Absence of heparan sulfate proteoglycans in Lewy bodies and Lewy neurites in Parkinson's disease brains.帕金森病大脑中路易小体和路易神经突中硫酸乙酰肝素蛋白聚糖的缺失。
J Alzheimers Dis. 2004 Oct;6(5):469-74. doi: 10.3233/jad-2004-6502.

引用本文的文献

1
Criterion for Assessing Accumulated Neurotoxicity of Alpha-Synuclein Oligomers in Parkinson's Disease.评估帕金森病中α-突触核蛋白寡聚体累积神经毒性的标准。
Int J Numer Method Biomed Eng. 2025 Apr;41(4):e70027. doi: 10.1002/cnm.70027.
2
Aberrant accumulation of phosphorylated BRCA1 in brainstem-type and cortical-type Lewy bodies in Lewy body disease.在路易体病的脑干型和皮质型路易小体中,磷酸化BRCA1异常积聚。
J Neuropathol Exp Neurol. 2025 Apr 1;84(4):276-285. doi: 10.1093/jnen/nlaf004.
3
14-3-3θ phosphorylation exacerbates alpha-synuclein aggregation and toxicity.
14-3-3θ磷酸化加剧α-突触核蛋白的聚集和毒性。
Neurobiol Dis. 2025 Mar;206:106801. doi: 10.1016/j.nbd.2025.106801. Epub 2025 Jan 11.
4
The BE (2)-M17 neuroblastoma cell line: revealing its potential as a cellular model for Parkinson's disease.BE(2)-M17神经母细胞瘤细胞系:揭示其作为帕金森病细胞模型的潜力。
Front Cell Neurosci. 2024 Nov 26;18:1485414. doi: 10.3389/fncel.2024.1485414. eCollection 2024.
5
14-3-3 phosphorylation inhibits 14-3-3θ's ability to regulate LRRK2 kinase activity and toxicity.14-3-3 磷酸化抑制 14-3-3θ 调节 LRRK2 激酶活性和毒性的能力。
Hum Mol Genet. 2024 Nov 20;33(23):2071-2083. doi: 10.1093/hmg/ddae142.
6
A-Syn(ful) MAM: A Fresh Perspective on a Converging Domain in Parkinson's Disease.α-突触核蛋白(过度)聚集型神经突黏液样小体:帕金森病领域融合研究的新视角。
Int J Mol Sci. 2024 Jun 13;25(12):6525. doi: 10.3390/ijms25126525.
7
Prospective Role of PAK6 and 14-3-3γ as Biomarkers for Parkinson's Disease.PAK6 和 14-3-3γ 作为帕金森病生物标志物的前瞻性作用。
J Parkinsons Dis. 2024;14(3):495-506. doi: 10.3233/JPD-230402.
8
14-3-3τ as a Modulator of Early α-Synuclein Multimerization and Amyloid Formation.14-3-3τ 作为早期 α-突触核蛋白寡聚化和淀粉样形成的调节剂。
ACS Chem Neurosci. 2024 May 1;15(9):1926-1936. doi: 10.1021/acschemneuro.4c00100. Epub 2024 Apr 18.
9
14-3-3 proteins-a moonlight protein complex with therapeutic potential in neurological disorder: in-depth review with Alzheimer's disease.14-3-3蛋白——一种在神经疾病中具有治疗潜力的多功能蛋白复合物:对阿尔茨海默病的深入综述
Front Mol Biosci. 2024 Feb 5;11:1286536. doi: 10.3389/fmolb.2024.1286536. eCollection 2024.
10
Formation of amyloid fibrils by the regulatory 14-3-3 protein.调节蛋白 14-3-3 形成淀粉样纤维。
Open Biol. 2024 Jan;14(1):230285. doi: 10.1098/rsob.230285. Epub 2024 Jan 17.